A 42-year-old woman with rheumatoid arthritis has been on naproxen 500 mg twice daily for 3 years with good disease control. She now presents with epigastric pain, nausea, and dark stools. Hemoglobin is 9.2 g/dL (baseline 12.5 g/dL). Upper endoscopy reveals a 1.5 cm antral ulcer with active bleeding. The ulcer is successfully treated with endoscopic hemostasis. What is the most appropriate next step in management?

Explanation

## Clinical Scenario: NSAID-Induced Peptic Ulcer Disease with Hemorrhage This patient has: - Chronic NSAID use (3 years) - Acute GI bleeding (hemodynamically significant: Hb drop of 3.3 g/dL) - Endoscopically confirmed ulcer with active bleeding - Successful hemostasis achieved ## Pathophysiology of NSAID Gastropathy **Key Point:** NSAIDs inhibit COX-1 in gastric mucosa, reducing protective prostaglandin (PGE₂, PGI₂) synthesis. This decreases: - Mucus secretion - Bicarbonate production - Mucosal blood flow Result: loss of mucosal defense and increased ulcer risk. ## Management Algorithm for NSAID-Induced GI Bleeding ```mermaid flowchart TD A[NSAID + active GI bleed]:::urgent --> B[Endoscopic hemostasis]:::action B --> C{Continue NSAID?}:::decision C -->|High-risk patient| D[Discontinue NSAID]:::action C -->|Low-risk, essential NSAID| E[Selective COX-2 inhibitor]:::action D --> F[Switch to acetaminophen or topical NSAID]:::action E --> G[Add PPI for 8 weeks minimum]:::action G --> H[Reassess at 8 weeks]:::outcome ``` ## Why Celecoxib + PPI is Optimal | Strategy | Rationale | Evidence | |----------|-----------|----------| | **Discontinue non-selective NSAID** | Reduces direct mucosal injury | Standard of care post-bleed | | **Switch to COX-2 inhibitor** | Preserves GI safety while maintaining anti-inflammatory effect | Celecoxib has lower GI toxicity than non-selective NSAIDs | | **Add PPI for 8 weeks** | Suppresses gastric acid, allows ulcer healing | Omeprazole 20 mg daily or equivalent | | **Reassess rheumatology needs** | May require DMARDs (methotrexate, biologics) as primary therapy | RA control should not depend on NSAIDs alone | **High-Yield:** After NSAID-induced GI bleeding, the patient should NOT resume the same non-selective NSAID. If an NSAID is absolutely necessary for RA, a selective COX-2 inhibitor (celecoxib) with a PPI is the safest option. **Clinical Pearl:** "Once an ulcer bleeds, NSAIDs are contraindicated" — this is a critical teaching point. The risk of recurrent bleeding is 20–30% if the same NSAID is restarted without gastroprotection. **Mnemonic:** **PPI-COX2** = Post-bleed, Inhibit acid + selective COX-2 inhibitor. ## Why Other Options Fail - **Restarting naproxen (even at lower dose):** Non-selective NSAIDs carry the same ulcer risk regardless of dose. Dose reduction does not prevent recurrence. - **H₂-receptor antagonist monotherapy:** H₂ blockers are inferior to PPIs for NSAID ulcer healing and do not provide adequate gastroprotection. - **Acetaminophen alone:** While safe, it may not provide adequate anti-inflammatory effect for RA. However, if the patient cannot tolerate any NSAID, this is acceptable with escalation to DMARDs.